A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Four 12-week Treatment Cycles (48 Weeks Total) of Epratuzumab in Systemic Lupus Erythematosus Subjects With Moderate to Severe Disease

The primary objective of the study is to confirm the clinical efficacy of epratuzumab in the treatment of subjects with Systemic Lupus Erythematosus (SLE).

本研究的主要目标为验证依帕珠单抗（epratuzumab）用于系统性红斑狼疮（Systemic Lupus Erythematosus, SLE）受试者治疗的临床疗效。